- Home
- RLX vs FOLD Comparison
RLX vs FOLD Comparison
Compare RLX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | FOLD |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | China | United States |
| Employees | N/A | 499 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RLX | FOLD |
|---|---|---|
| Price | $2.35 | $9.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.25 | ★ $30.29 |
| AVG Volume (30 Days) | 2.1M | ★ 4.4M |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.56% | N/A |
| EPS Growth | ★ 19.33 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $459,694,770.00 | ★ $598,704,000.00 |
| Revenue This Year | $63.02 | $21.12 |
| Revenue Next Year | $24.72 | $21.23 |
| P/E Ratio | $29.42 | ★ N/A |
| Revenue Growth | ★ 51.58 | 21.28 |
| 52 Week Low | $1.66 | $5.51 |
| 52 Week High | $2.84 | $10.57 |
Technical Indicators
Market Signals| Indicator | RLX | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 62.51 |
| Support Level | $2.42 | $9.73 |
| Resistance Level | $2.47 | $10.05 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 6.12 | 45.24 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.